Prevention of Persistence of Bacterial Vaginosis

NCT ID: NCT00741845

Last Updated: 2012-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

117 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This purpose of this study will be to conduct a double-blind, randomized, controlled clinical trial to determine the association between intravaginal high dose metronidazole (750mg), intravaginal high dose metronidazole combined with an antifungal agent(750mg metronidazole + 200mg miconazole) and low dose (37.5mg) intravaginal metronidazole, with the rate of persistent bacterial vaginosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Vaginosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

intravaginal metronidazole 750mg + 200mg miconazole

Group Type ACTIVE_COMPARATOR

intravaginal metronidazole

Intervention Type DRUG

high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg

2

intravaginal metronidazole 750mg

Group Type ACTIVE_COMPARATOR

intravaginal metronidazole

Intervention Type DRUG

high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg

3

intravaginal metronidazole 37.5mg

Group Type ACTIVE_COMPARATOR

intravaginal metronidazole

Intervention Type DRUG

high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intravaginal metronidazole

high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women 18-40 yrs old
* abnormal vaginal discharge or malodor
* positive QuickVue test
* positive KOH whiff test
* Positive finding of clue cells greater than or equal to 20% on wet mount
* Able to give informed consent
* willing to abstain from alcohol during the 5 day therapy and 1 day following

Exclusion Criteria

* immunocompromised women
* symptomatic VVC
* pregnancy or positive pregnancy test
* menstruating or breastfeeding women
* other oral or vaginal antifungal or antimicrobial drugs w/in past 2 wks
* women with MPC, PID
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Embil Pharmaceutical Co. Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cayetano Heredia Hospital

Lima, Urb Ingenieria, Peru

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Peru

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Embil-2008Peru

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vaginal Infection Study 2
NCT00694928 COMPLETED PHASE3
Vaginal Infection Study
NCT00616330 COMPLETED PHASE3